Cantor Fitzgerald Starts Accelrys (ACCL) at Buy; Scientific R&D Enhanced with Software

Cantor Fitzgerald initiates coverage on Accelrys (NASDAQ: ACCL) with a Buy. PT $10.00.

Analyst, Sung Ji Nam, said, "Since the merger with comparably-sized software provider Symyx in mid-2010, ACCL has focused on integration, restructuring, and strengthening its product portfolio over the last 18+ months. Although both ACCL and Symyx as standalone companies have struggled with top-line growth over several years, we believe the combined company has emerged better positioned to capitalize on high-growth opportunities within the scientific informatics market."

Nam expects Under-penetrated non-life sciences markets will also represent meaningful growth drivers...Strong balance sheet should help add tuck-in acquisitions of complementary assets.

For an analyst ratings summary and ratings history on Accelrys click here. For more ratings news on Accelrys click here.

Shares of Accelrys closed at $8.03 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral
• Leerink Starts Ligand Pharma (LGND) at Outperform
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald